Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis

Journal of the American College of Cardiology

Volumn 63, Issue 6, 2014, Pages 537-538

  Pitt, Bertram ^a   Rossignol, Patrick ^b,c,d,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e Association Lorraine Pour le Traitement de l'Insuffisance Ré Nale   (France)

Author keywords

cardiovascular and cerebrovascular event; hemodialysis; spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; EPLERENONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; FOLLOW UP; HEART FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; NOTE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD VESSEL CALCIFICATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG SAFETY; END STAGE RENAL DISEASE; FIBROSIS; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); OXIDATIVE STRESS; RISK FACTOR;

CARDIOVASCULAR AND CEREBROVASCULAR EVENT; HEMODIALYSIS; SPIRONOLACTONE;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84893840316     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.057     Document Type: Editorial

References (18)

1. A. Remppis, and E. Ritz Cardiac problems in the dialysis patient: beyond coronary disease Semin Dial 21 2008 319 325
2. C. Wanner, V. Krane, W. Marz, and M. Olschewski et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
3. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, and H. Holdaas et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
4. G. Cice, L. Ferrara, A. D'Andrea, and S. D'Isa et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial J Am Coll Cardiol 41 2003 1438 1444 (Pubitemid 36543357)
5. G. Cice, A. Di Benedetto, and S. D'Isa et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial J Am Coll Cardiol 56 2010 1701 1708
6. F. Zannad, M. Kessler, and P. Lehert et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 2006 1318 1324 (Pubitemid 44435184)
7. R. Agarwal Blood pressure and mortality among hemodialysis patients Hypertension 55 2010 762 768
8. B. Pitt, F. Zannad, and W.J. Remme et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
9. B. Pitt, W. Remme, and F. Zannad et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
10. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
11. W. Iraqi, P. Rossignol, and M. Angioi et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study Circulation 119 2009 2471 2479
12. N.J. Brown Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis Nat Rev Nephrol 9 2013 459 469
13. J. Voelkl, I. Alesutan, and C.B. Leibrock et al. Spironolactone ameliorates pit1-dependent vascular osteoinduction in klotho-hypomorphic mice J Clin Invest 123 2013 812 822
14. J.P. Bertocchio, D.G. Warnock, and F. Jaisser Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease Kidney Int 79 2011 1051 1060
15. N.C. Edwards, R.P. Steeds, P.M. Stewart, C.J. Ferro, and J.N. Townend Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 2009 505 512
16. L. Shavit, M.D. Lifschitz, and M. Epstein Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms Kidney Int 81 2012 955 968
17. K. Nitta, T. Akiba, and H. Nihei Aldosterone blockade and vascular calcification in hemodialysis patients Am J Med 115 2003 250 (Pubitemid 37338154)
18. Y. Matsumoto, Y. Mori, and S. Kageyama et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients J Am Coll Cardiol 63 2014 528 536